Gordian Biotechnologies is a privately held biotechnology company developing a portfolio of first-in-class non-covalently bound reversible β-lactamase inhibitors that allow existing antibiotics to be effective against otherwise resistant pathogens. Its third generation BLI is specifically designed to target Extended spectrum beta-lactamase (ESBL) resistance and render it ineffective.
β‑lactamases are enzymes produced by bacteria that destroy the antibiotic activity of β‑lactam antibiotics, such as penicillin derivatives, cephalosporins, monobactams and carbapenems. For more information on β‑lactamases and our candidate inhibitors, visit our Research & Development page.
By combining a FDA approved antibiotic with our novel first-in-class β-lactamase inhibitors, these compounds can disarm the bacteria’s resistance mechanism, allowing the antibiotic to defeat the pathogen.
Gordian Biotechnologies has an exclusive global license to technology developed jointly at the University of South Florida and the University of California at San Francisco for a portfolio of first-in-class reversible β-lactamase inhibitors that are designed to treat drug-resistant infections.
Gordian Biotechnologies was founded in 2014 and is headquartered in West Palm Beach, FL
Gordian Biotechnologies possesses a critical asset in the expertise of its Management Team, Board of Directors, and Scientific and Business Advisory Boards. Chief Executive Tony Brazzale, with his vision, scientific background and enthusiasm, has assembled a team of top professionals to join him in guiding Gordian. Management is comprised of highly experienced professionals with entrepreneurial experience as well as large pharma experience across many facets of the life sciences industries.